<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979182</url>
  </required_header>
  <id_info>
    <org_study_id>8209</org_study_id>
    <nct_id>NCT04979182</nct_id>
  </id_info>
  <brief_title>Clinical Characterization of Frequent Monogenic Forms of Neurodevelopmental Disorders</brief_title>
  <acronym>MONOGENETND</acronym>
  <official_title>Somatic and Neurobehavioral Clinical Characterization of Frequent Monogenic Forms of Neurodevelopmental Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to constitute a precise and exhaustive collection of clinical data&#xD;
      (somatic and neurobehavioral data) of individuals affected by various frequent monogenic&#xD;
      forms of neurodevelopmental disorders to better characterize the clinical phenotype of these&#xD;
      disorders.&#xD;
&#xD;
      A better knowledge of these manifestations is necessary to improve the management of&#xD;
      individuals with these disorders.&#xD;
&#xD;
      The secondary objectives of this research are to inform practitioners, patients and their&#xD;
      families about the clinical characteristics of these disorders to better understand their&#xD;
      diversity and, finally, to improve their screening and diagnosis. Thus, our study aims at&#xD;
      establishing clinical scores, linking genotypes and phenotypes and producing documents for&#xD;
      professionals (such as the PNDS (National Diagnostic and Care Protocols))&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of clinical profiles associated to different monogenic form of NDD</measure>
    <time_frame>Files analysed retrospectively from January 01, 2015 to March 31, 2020 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neurodevelopmental Disorders</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient treated for TND linked to a mutation in one of the genes frequently mutated in this&#xD;
        pathology, such as the DYRK1A, KMT2A or other genes&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Minor patient whose age is ≥ 4 years and ≤18 years&#xD;
&#xD;
          -  Major patient with intellectual disability&#xD;
&#xD;
          -  Patient treated in a participating center for TND linked to a mutation in one of the&#xD;
             genes frequently mutated in this pathology, such as the DYRK1A, KMT2A or other genes;&#xD;
&#xD;
          -  Patient having previously been seen in genetic consultation&#xD;
&#xD;
          -  Parent (or legal guardian) not having expressed, after information, his opposition to&#xD;
             the reuse of his data for the purposes of this research.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Parent (or legal guardian) who expressed his opposition to participating in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amélie PITON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Génétique Moléculaire Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amélie PITON, MD</last_name>
    <phone>33 3 69 55 16 52</phone>
    <email>amelie.piton@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <phone>33 3 88 11 66 90</phone>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Génétique Moléculaire Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PITON PITON, MD</last_name>
      <phone>33 3 69 55 16 52</phone>
      <email>amelie.piton@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <phone>33 3 88 11 66 90</phone>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Amélie PITON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Romain COUTELLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen SCHRODER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elise SCHAEFER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin DURAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent LAUGEL, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>July 16, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurodevelopmental disorders</keyword>
  <keyword>Rare disease</keyword>
  <keyword>Genetic Diseases</keyword>
  <keyword>Monogenic syndromes</keyword>
  <keyword>Intellectual Disability</keyword>
  <keyword>Autism spectrum disorder</keyword>
  <keyword>Neurobehavioral Manifestations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Neurodevelopmental Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

